PIPA: A phase Ib study of β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer.

被引：6
|
作者：
Pascual, Javier
MacPherson, Iain R.
Armstrong, Anne Caroline
Ward, Sarah Emily
Parmar, Mona
Turner, Alison Joanne
Bye, Hannah
Proszek, Paula
Dodson, Andrew
Garcia-Murillas, Isaac
King, Jenny
Hall, Emma
Finneran, Laura
Lopez, Juanita Suzanne
Okines, Alicia Frances Clare
Ring, Alistair E.
Turner, Nicholas C.
机构：
[1] Royal Marsden Hosp, London, England
[2] Inst Canc Res, London, England
[3] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[4] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[5] Inst Canc Res, Sutton, Surrey, England
[6] Royal Marsden Inst Canc Res, London, England
[7] Royal Marsden NHS Fdn Trust, London, England
[8] Inst Canc Res, Clin Trials & Stat Unit, London, England
[9] Inst Canc Res, Drug Dev Unit, Sutton, Surrey, England
[10] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.1051
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1051
引用
收藏
页数：2
相关论文
共 46 条
  • [41] BYLieve: A phase II study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of PIK3CA mutant, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy.
    Rugo, Hope S.
    Bianchi, Giulia Valeria
    Chia, Stephen K. L.
    Turner, Nicholas C.
    Juric, Dejan
    Jacot, William
    Borrego, Manuel Ruiz
    Chap, Linnea I.
    Brown-Glaberman, Ursa Abigail
    Nienstedt, Carolyn C.
    Sophos, Nikos
    Ridolfi, Antonia
    Lin, Chinjune
    Ciruelos, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] First-line inavolisib/placebo plus palbociclib plus fulvestrant (Inavo/Pbo plus Palbo plus Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses
    Juric, Dejan
    Kalinsky, Kevin
    Turner, Nicholas C.
    Jhaveri, Komal L.
    Schmid, Peter
    Loi, Sherene
    Saura, Cristina
    Im, Seock-Ah
    Sunpaweravong, Patrapim
    Li, Huiping
    Musolino, Antonino
    Zhang, Qingyuan
    Nowecki, Zbigniew
    Leung, Roland Ching-Yu
    Thanopoulou, Eirini
    Shankar, Noopur
    Lei, Guiyuan
    Devine, Jacob
    Stout, Thomas J.
    Loibl, Sibylle
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] EPIK-B5: A phase III, randomized study of alpelisib (ALP) plus fulvestrant (FUL) in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) progressing on/after an aromatase inhibitor (AI) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i).
    De Laurentiis, Michelino
    Costa, Luis
    Gligorov, Joseph
    Knop, Ann
    Senkus-Konefka, Elzbieta
    Garcia-Saenz, Jose A.
    Schmid, Peter
    Heniquez, Aurelia
    Serra, Paolo
    Reising, Albert
    Kuemmel, Sherko
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] Alpelisib plus letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results
    Rugo, Hope S.
    Lerebours, Florence
    Juric, Dejan
    Turner, Nicholas
    Chia, Stephen
    Drullinsky, Pamela
    Prat, Aleix
    Villanueva Vazquez, Rafael
    Akdere, Murat
    Arce, Christina
    Shen, Yu-Ming
    Ciruelos, Eva
    CANCER RESEARCH, 2021, 81 (04)
  • [45] EPIK-B4: A phase 2, randomized study of metformin (MET) extended release (XR) plus /dapagliflozin (DAPA) to prevent hyperglycemia (HG) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC) treated with alpelisib (ALP) and fulvestrant (FUL).
    Gradishar, William John
    Farooki, Azeez
    Giridhar, Karthik
    Moore, Heather
    Johnston, Abigail
    Miller, Michelle Kristine
    Wang, Craig
    Reising, Albert
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Alpelisib plus endocrine therapy (ET) in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study
    Juric, Dejan
    Turner, Nicholas
    Prat, Aleix
    Chia, Stephen
    Ciruelos, Eva M.
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Lerebours, Florence
    Bachelot, Thomas
    Balbin, O. Alejandro
    Joshi, Mukta
    Roux, Estelle
    Arce, Christina H.
    Akdere, Murat
    Rugo, Hope S.
    CANCER RESEARCH, 2022, 82 (04)
12345